A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.
Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naïve adults and...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3823848?pdf=render |
id |
doaj-96190709ca5249a088f8c688c8a52167 |
---|---|
record_format |
Article |
spelling |
doaj-96190709ca5249a088f8c688c8a521672020-11-25T01:42:24ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01811e7867910.1371/journal.pone.0078679A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age.Alphonse OuédraogoAlfred B TionoDésiré KargougouJean Baptiste YaroEsperance OuédraogoYoussouf KaboréDavid KangoyeEdith C BougoumaAdama GansaneNoelie HenriAmidou DiarraSouleymane SanonIssiaka SoulamaAmadou T KonateNora L WatsonValerie BrownJenny HendriksMaria Grazia PauIsabella VersteegeEdison WieskenJerald SadoffIssa NebieSodiomon B SirimaAd35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naïve adults and showed that the vaccine was safe. The aim of this study is to assess the safety and immunogenicity of ascending dosages in sub Saharan Africa.A double blind, randomized, controlled, dose escalation, phase Ib trial was conducted in a rural area of Balonghin, the Saponé health district (Burkina Faso). Forty-eight healthy adults aged 18-45 years were randomized into 4 cohorts of 12 to receive three vaccine doses (day 0, 28 and 84) of 10(9), 10(10), 5X10(10), 10(11) vp of Ad35.CS.01 or normal saline by intra muscular injection. Subjects were monitored carefully during the 14 days following each vaccination for non serious adverse events. Severe and serious adverse events were collected throughout the participant study duration (12 months from the first vaccination). Humoral and cellular immune responses were measured on study days 0, 28, 56, 84, 112 and 140.Of the forty-eight subjects enrolled, forty-four (91.7%) received all three scheduled vaccine doses. Local reactions, all of mild severity, occurred in thirteen (27.1%) subjects. Severe (grade 3) laboratory abnormalities occurred in five (10.4%) subjects. One serious adverse event was reported and attributed to infection judged unrelated to vaccine. The vaccine induced both antibody titers and CD8 T cells producing IFNγ and TNFα with specificity to CS while eliciting modest neutralizing antibody responses against Ad35.Study vaccine Ad35.CS.01 at four different dose levels was well-tolerated and modestly immunogenic in this population. These results suggest that Ad35.CS.01 should be further investigated for preliminary efficacy in human challenge models and as part of heterologous prime-boost vaccination strategies.ClinicalTrials.gov NCT01018459 http://clinicaltrials.gov/ct2/show/NCT01018459.http://europepmc.org/articles/PMC3823848?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alphonse Ouédraogo Alfred B Tiono Désiré Kargougou Jean Baptiste Yaro Esperance Ouédraogo Youssouf Kaboré David Kangoye Edith C Bougouma Adama Gansane Noelie Henri Amidou Diarra Souleymane Sanon Issiaka Soulama Amadou T Konate Nora L Watson Valerie Brown Jenny Hendriks Maria Grazia Pau Isabella Versteege Edison Wiesken Jerald Sadoff Issa Nebie Sodiomon B Sirima |
spellingShingle |
Alphonse Ouédraogo Alfred B Tiono Désiré Kargougou Jean Baptiste Yaro Esperance Ouédraogo Youssouf Kaboré David Kangoye Edith C Bougouma Adama Gansane Noelie Henri Amidou Diarra Souleymane Sanon Issiaka Soulama Amadou T Konate Nora L Watson Valerie Brown Jenny Hendriks Maria Grazia Pau Isabella Versteege Edison Wiesken Jerald Sadoff Issa Nebie Sodiomon B Sirima A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS ONE |
author_facet |
Alphonse Ouédraogo Alfred B Tiono Désiré Kargougou Jean Baptiste Yaro Esperance Ouédraogo Youssouf Kaboré David Kangoye Edith C Bougouma Adama Gansane Noelie Henri Amidou Diarra Souleymane Sanon Issiaka Soulama Amadou T Konate Nora L Watson Valerie Brown Jenny Hendriks Maria Grazia Pau Isabella Versteege Edison Wiesken Jerald Sadoff Issa Nebie Sodiomon B Sirima |
author_sort |
Alphonse Ouédraogo |
title |
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. |
title_short |
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. |
title_full |
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. |
title_fullStr |
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. |
title_full_unstemmed |
A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. |
title_sort |
phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in burkinabe healthy adults 18 to 45 years of age. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2013-01-01 |
description |
Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phase 1a trial has been conducted in the USA in naïve adults and showed that the vaccine was safe. The aim of this study is to assess the safety and immunogenicity of ascending dosages in sub Saharan Africa.A double blind, randomized, controlled, dose escalation, phase Ib trial was conducted in a rural area of Balonghin, the Saponé health district (Burkina Faso). Forty-eight healthy adults aged 18-45 years were randomized into 4 cohorts of 12 to receive three vaccine doses (day 0, 28 and 84) of 10(9), 10(10), 5X10(10), 10(11) vp of Ad35.CS.01 or normal saline by intra muscular injection. Subjects were monitored carefully during the 14 days following each vaccination for non serious adverse events. Severe and serious adverse events were collected throughout the participant study duration (12 months from the first vaccination). Humoral and cellular immune responses were measured on study days 0, 28, 56, 84, 112 and 140.Of the forty-eight subjects enrolled, forty-four (91.7%) received all three scheduled vaccine doses. Local reactions, all of mild severity, occurred in thirteen (27.1%) subjects. Severe (grade 3) laboratory abnormalities occurred in five (10.4%) subjects. One serious adverse event was reported and attributed to infection judged unrelated to vaccine. The vaccine induced both antibody titers and CD8 T cells producing IFNγ and TNFα with specificity to CS while eliciting modest neutralizing antibody responses against Ad35.Study vaccine Ad35.CS.01 at four different dose levels was well-tolerated and modestly immunogenic in this population. These results suggest that Ad35.CS.01 should be further investigated for preliminary efficacy in human challenge models and as part of heterologous prime-boost vaccination strategies.ClinicalTrials.gov NCT01018459 http://clinicaltrials.gov/ct2/show/NCT01018459. |
url |
http://europepmc.org/articles/PMC3823848?pdf=render |
work_keys_str_mv |
AT alphonseouedraogo aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT alfredbtiono aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT desirekargougou aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jeanbaptisteyaro aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT esperanceouedraogo aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT youssoufkabore aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT davidkangoye aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT edithcbougouma aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT adamagansane aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT noeliehenri aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT amidoudiarra aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT souleymanesanon aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT issiakasoulama aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT amadoutkonate aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT noralwatson aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT valeriebrown aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jennyhendriks aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT mariagraziapau aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT isabellaversteege aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT edisonwiesken aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jeraldsadoff aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT issanebie aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT sodiomonbsirima aphase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT alphonseouedraogo phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT alfredbtiono phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT desirekargougou phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jeanbaptisteyaro phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT esperanceouedraogo phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT youssoufkabore phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT davidkangoye phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT edithcbougouma phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT adamagansane phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT noeliehenri phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT amidoudiarra phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT souleymanesanon phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT issiakasoulama phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT amadoutkonate phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT noralwatson phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT valeriebrown phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jennyhendriks phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT mariagraziapau phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT isabellaversteege phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT edisonwiesken phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT jeraldsadoff phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT issanebie phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage AT sodiomonbsirima phase1brandomizedcontrolleddoubleblindeddosageescalationtrialtoevaluatethesafetyreactogenicityandimmunogenicityofanadenovirustype35basedcircumsporozoitemalariavaccineinburkinabehealthyadults18to45yearsofage |
_version_ |
1725036651595431936 |